MapLight Therapeutics, Inc. Common Stock (MPLT) - Total Liabilities
Based on the latest financial reports, MapLight Therapeutics, Inc. Common Stock (MPLT) has total liabilities worth $21.14 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of MapLight Therapeutics, Inc. Common Stock to track the company's year-over-year net asset growth rate.
MapLight Therapeutics, Inc. Common Stock - Total Liabilities Trend (2022–2025)
This chart illustrates how MapLight Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
MapLight Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of MapLight Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Beijing Trust Far Tech
SHE:300231
|
China | CN¥815.28 Million |
|
Shenzhen Jiawei Photovoltaic Lighting Co Ltd
SHE:300317
|
China | CN¥1.48 Billion |
|
Blue Moon Zinc Corp
V:MOON
|
Canada | CA$39.66 Million |
|
Kid ASA
OL:KID
|
Norway | Nkr3.13 Billion |
|
Wam Global Ltd
AU:WGB
|
Australia | AU$1.68 Million |
|
Zhejiang Xiantong Rubber&Plastic Co Ltd
SHG:603239
|
China | CN¥400.42 Million |
|
Ambassador Hotel Ltd
TW:2704
|
Taiwan | NT$8.09 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$732.53 Million |
Liability Composition Analysis (2022–2025)
This chart breaks down MapLight Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see MapLight Therapeutics, Inc. Common Stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 20.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MapLight Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MapLight Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual total liabilities of MapLight Therapeutics, Inc. Common Stock from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $21.14 Million | -2.67% |
| 2024-12-31 | $21.72 Million | +7.92% |
| 2023-12-31 | $20.13 Million | +8.68% |
| 2022-12-31 | $18.52 Million | -- |
About MapLight Therapeutics, Inc. Common Stock
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irrit… Read more